Samelisant is under clinical development by Suven Life Sciences and currently in Phase II for Narcolepsy. According to GlobalData, Phase II drugs for Narcolepsy have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Samelisant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Samelisant overview
Samelisant (SUVNG-3031) is under development for the treatment of cognitive impairment associated with Alzheimer's disease, schizophrenia, narcolepsy and narcolepsy associated with cataplexy. The drug candidate is administered orally in the form of tablet. The drug candidate acts by targeting histamine 3 (H3) receptor.
Suven Life Sciences overview
Suven Life Sciences (Suven), formerly Suven Pharmaceuticals, provides drug discovery and development support services. The company offers research services specializing in drug metabolism and pharmacokinetics; CNS pharmacology including behavioral pharmacology, microdialysis, receptor occupancy and electrophysiology; toxicology and safety pharmacology; bioanalysis, synthetic, medicinal and analytical chemistry; in-vitro assay development and screening; and NCE formulations. Its product pipeline includes Masupirdine, Samelisant, Usmarapride, Ropanicant, SUVN-M8036 and SUVN-D1044. Suven’s therapeutic areas include alzheimer’s diseases, neuropsychiatric, narcolepsy, cognitive disorders, depressive disorders, psychiatric disorders, and gastro-intestinal disorders. The company operates its offices in India. Suven is headquartered in Hyderabad, Telangana, India.
For a complete picture of Samelisant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
